Compare Abeona Therapeutics Inc (ABEO) vs Celsius Holdings, Inc. (CELH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Celsius Holdings, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Celsius Holdings, Inc. trades at $30.57 (market cap $8.10B). The key difference: Celsius Holdings, Inc. is far larger — about 21.7× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Celsius Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| ABEO | CELH | |
|---|---|---|
Market Cap | $373.32M | $8.10B |
Sector | Health | Consumer Staples |
52-Week High | $7.23 | $64.86 |
52-Week Low | $4.17 | $27.75 |
Enterprise Value | $228.22M | $9.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Celsius Holdings (CELH) trades at $31.70, down 4.4% on the day, with strong analyst consensus (95.65% buy ratings) and a $53.11 price target. Recent quarters show consistent earnings beats, with Q1 2026 EPS of $0.41 beating expectations of $0.29. Revenue growth is robust, projected at $3.0B for 2026, though net margins have compressed from 17.2% in 2023 to 4.29% in 2025. Technical indicators show a bullish moving average trend but neutral oscillators, with key resistance at $34.
The outlook remains positive driven by international expansion and functional beverage demand, but risks include margin pressure, ongoing legal investigations, and high valuation multiples. The stock offers significant upside to consensus targets if growth execution continues, though investor sentiment is tempered by near-term profitability concerns and competitive threats.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Celsius Holdings, Inc.
Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →
